Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients

Table 4 Bivariate and multivariate analysis of factors associated with an outcome of HIV-1 RNA <200 copies/mL at week 48 of antiretroviral treatment

Risk factor	OR unadjusted	95 % CI	P	OR adjusted	95 % CI	P
Male gender	2.06	0.64–6.60	0.179
Age >40 years	0.23	0.08–0.66	0.004	0.15	0.04–0.52	0.003
Duration of ART >14 years	0.55	0.21–1.43	0.218
Number of previous regimens ≥6	1.40	0.45–4.33	0.372
Baseline HIV-1 RNA >100,000 copies/mL	3.19	1.13–8.94	0.022	2.83	0.80–9.94	0.103
Baseline CD4+ cells count <200 cells/μL	2.66	1.02–6.96	0.041	2.65	0.80–8.76	0.109
Number of mutations to DRV ≥2	1.20	0.46–3.12	0.703
GSS in OBR <1 vs. ≥1	1.05	0.95–1.15	0.175
GSS in OBR ≤1 vs. >1	0.759	0.22–2.57	0.435
GSS in OBR <2 vs. ≥2	0.615	0.22–1.72	0.352
TDF in regimen	4.06	1.12–14.7	0.018	4.16	1.02–16.8	0.046
MVC in regimen	1.48	0.37–5.93	0.575
ENF in regimen	1.48	0.37–5.93	0.406
ETV in regimen	0.56	0.17–1.83	0.340
RAL in regimen	0.22	0.06–0.72	0.008	0.32	0.08–1.24	0.101

DRV darunavir, ENF enfuvirtide, ETV etravirine, GSS genotypic susceptibility score, MVC maraviroc, PI protease inhibitor, RAL raltegravir, RAM resistance-associated mutation, TDF tenofovir

ISSN: 1742-6405